Riskpilot← Back to searchSign inGet full accessUnimedic Pharma AB
ABActiveOrg 5565579967Sundbybergsvägen 1Wholesale of pharmaceutical and medical goods · NACE 4646Est. 199832 employees
Revenue 2024
SEK 335,1M
-12% vs 2023
EBITDA margin
10.5%
-58% vs 2023
Equity ratio
47.7%
Financial strength
Net profit 2024
SEK 18,3M
-53% vs 2023
| Revenue | SEK 335,1M | -12% |
| EBITDA | SEK 35,1M | -58% |
| Net profit | SEK 18,3M | -53% |
| Total assets | SEK 197,2M | -1% |
| Equity | SEK 94M | +24% |
| Employees | 32 | — |
Legal name
Unimedic Pharma AB
Org number
5565579967
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
6 juli 1998
Share capital
SEK 200 000
Employees
32 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna suppleanten
Company purpose
Bolaget ska bedriva handel med läkemedel och apoteksvaror samt förvalta aktier, värdepapper, fast och lös egendom samt därmed förenlig verksamhet.
Address
Sundbybergsvägen 1
Phone
+46101309950
Email
info@unimedicpharma.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 219 192 | 239 156 | 242 845 | 248 248 | 315 501 | 381 109 | 335 088 |
| Staff expenses | — | — | — | — | — | — | — | — | — |
| EBITDA | 25 847 | 8 988 | 15 294 | 22 793 | 25 675 | 37 533 | 76 665 | 82 828 | 35 109 |
| Depreciation & amort. | −376 | −425 | −1 419 | −4 241 | −5 541 | −6 587 | −7 354 | −7 385 | −5 623 |
| EBIT | 25 471 | 8 563 | 13 875 | 18 552 | 20 134 | 30 946 | 69 311 | 75 443 | 29 486 |
| Net financials | −696 | −649 | −1 222 | −1 696 | −2 270 | −772 | −2 215 | −3 212 | −4 194 |
| Profit before tax | 15 713 | −267 | 689 | 9 483 | −318 | 6 912 | 21 055 | 48 946 | 23 099 |
| Tax | −3 547 | −0 | −0 | −2 068 | −0 | −1 408 | −4 402 | −10 129 | −4 800 |
| Net profit | 12 166 | −267 | 689 | 7 415 | −318 | 5 504 | 16 653 | 38 817 | 18 299 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 77 921 | 81 170 | 100 076 | 102 692 | 115 911 | 136 559 | 198 791 | 199 418 | 197 188 |
| Equity | 15 772 | 15 545 | 16 234 | 15 032 | 14 714 | 20 218 | 36 870 | 75 687 | 93 986 |
| Long-term debt | 5 249 | 8 990 | 18 766 | 27 337 | 36 495 | 55 518 | 76 901 | 66 226 | 66 820 |
| Short-term debt | 55 628 | 56 635 | 65 076 | 60 323 | 64 702 | 60 823 | 85 020 | 57 505 | 36 382 |
| Total debt | 60 877 | 65 625 | 83 842 | 87 660 | 101 197 | 116 341 | 161 921 | 123 731 | 103 202 |
EBITDA margin
10.5%
This company
15.8%
Market median
-34% vs market
20162024
Equity ratio
47.7%
This company
38.2%
Market median
+25% vs market
20162024
Return on equity
19.5%
This company
18.4%
Market median
+6% vs market
20162024
Net profit margin
5.5%
This company
8.1%
Market median
-32% vs market
20162024
Asset turnover
1.70×
This company
1.12×
Market median
+52% vs market
20162024
Debt / equity
1.10×
This company
0.62×
Market median
-77% vs market
20162024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-05-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-05-01 – 2016-04-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
OC Chief Auditor | Chief Auditor | 2025 | — | — |
PJ Chief Auditor | Chief Auditor | 2020 | — | — |
BF Chief Auditor | Chief Auditor | 2020 | — | — |
JE Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2022 | — | — | |
| Chairman | 2025 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Board of Directors | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Unimedic Pharma Holding AB | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
MedCap AB (publ)
Unimedic Pharma AB Board members of Unimedic Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ola Christopher Carelius Larsmon | Chief Auditor | 0 companies |
| Per Johan Engstam | Chief Auditor | 0 companies |
| Björn Fredrik Sjölander | Chief Auditor | 0 companies |
| Johan Emil Frödin | Chief Executive Officer | 0 companies |
| Anders Dahlberg | Deputy Board Member | 0 companies |
| Per Anders Larnholt | Chairman | 0 companies |
| Snickar Karl Johan Tobieson | Deputy Board Member | 0 companies |
| Anna Valborg Elisabeth Linton | Board of Directors | 0 companies |